Skip to main content

Table 3 Subjects subgroups characteristics

From: Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia

Variable

HTG with obesity (n = 48)

HTG without obesity (n = 21)

NTG with obesity (n = 13)

NTG without obesity (n = 17)

P

WHR

0.92 ± 0.05c, e

0.82 ± 0.04d

0.91 ± 0.04e

0.80 ± 0.03

<0.001

Fasting parameters a

Triglycerides (mg/dL)

275 [201–345]d, e

271 [185–346]d, e

126 [103–136]

105 [79–131]

<0.001

Cholesterol (mg/dL)

226.9 ± 37.2d, e

228.8 ± 38.9

206.3 ± 18.9

197.5 ± 34.9

0.010

LDL-c (mg/dL)

129.4 ± 26.4

141.9 ± 44.7

133.7 ± 16.7

129.3 ± 24.9

0.604

Non HDL-c (mg/dL)

173.3 ± 27.2

181.6 ± 41.7d, e

157.7 ± 16.1

150 ± 29.4

0.014

Apo B (mg/dL)

123.2 ± 24.9d, e

122.3 ± 23.1

109.1 ± 11.8

107.3 ± 24.2

<0.001

Apo B-48 (μg/mL)b

6.5 [5.4–8.9]d, e

6.7 [3–7.4]d

1.5 [0.9–2.9]

3.1 [1.3–4.6]

<0.001

Apo A-V (ng/mL)b

365.5

303.3

215.5

287.9

0.096

[301.7–408.3]

[268.4–374.3]

[187.5–326.2]

[267.5–329.8]

Glucose (mg/dL)

103 [95–110]d, e

97 [92–107]

96 [91–101]

91 [87–94]

0.001

Insulin (μU/mL)

11.15 [7.7–13.4]d, e

8.6 [5.6–12.6]

7.6 [6.1–9.5]

8.9 [5.1–9.8]

0.029

HOMA-IR

2.73 [1.91–3.61]d, e

2.03 [1.45–3.21]

1.89 [1.41–2.5]

2.04 [1.28–2.29]

0.010

AST (IU/L)

30 [25–33]d

26 [24–33]

25 [21.5–28]

25 [22–27]

0.073

ALT (IU/L)

30 [21–37]d, e

22 [18–34]

19.5 [15–25]

20 [16–30]

0.015

GGT (IU/L)

28 [18–38]

19 [15–47]

23.5 [10–34.5]

15 [13–29]

0.085

Apo B-48/apo Bb

0.056 ± 0.0d

0.046 ± 0.02

0.015 ± 0.00

0.041 ± 0.02

0.035

Apo A-V/triglyceridesb

1.29 [1.02–1.73]e

1.10 [0.87–1.54]e

1.84 [1.60–2.48]

3.06 [2.24–4.27]

0.001

Postprandial parameters

Triglycerides iAUC

777.2

576.5

433

439.5

<0.001

(mg/dL/h)

[548.5–1092.7]d, e

[213–1028]

[280–595.5]

[243.5–568.5]

Triglycerides peak (mg/dL)

444.5 [353–562]d, e

444 [268–570]d, e

228 [188–291]

211 [180–231]

<0.001

Triglycerides time to peak (h)

5 [4–6]

4 [4–5]

4 [4–5]

3 [3–4]

0.075

Apo B-48 iAUC (μg/mL/h)b

27.1 [15.3–49.3]

23.6 [11.6–29.3]

15 [10.8–23.4]

18.7 [8.7–24.6]

0.373

Apo B-48 peak (μg/mL)b

15.8 [11.6–22.2]d, e

14 [7–16.7]

4.2 [3.1–7.4]

7.4 [3.9–10]

0.002

Apo B-48 time to peak (h)b

6 [4–8]e

6 [4–8]e

5 [3.5–6]

4 [3–4]

0.024

Apo A-V iAUC

1132.9

707.8

363.8

145.1

0.002

(ng/mL/h)b

[826.4–1474.7]d, e

[72.6–1533.8]

[145.0–480.5]

[–5.8–453.0]

Apo A-V peak

603.4

459

323.2

358.6

<0.001

(ng/mL)b

[534–673.7]d, e

[382.9–613.9]

[226.7–439.3]

[299.2–423.9]

Apo A-V time to peak (h)b

6 [4–6]e

4 [4–6]

5 [3.5–6]

3 [3–4]

0.006

  1. Data are expressed as means ± SD or medians [IQR]. HTG: hypertriglyceridemia defined as fasting triglycerides ≥150 mg/dL. Obesity defined as waist to hip ratio (WHR) ≥0.92 in males and ≥0.85 in females. NTG: normotriglyceridemia defined as fasting triglycerides <150 mg/dL. aAll study subjects had apo B levels over the 90th percentile for the Mexican population and HTG and/or hypercholesterolemia at diagnosis; however, some of them showed inferior levels at the time of the study due to the already known variability in the lipid profile associated with FCH.
  2. bN = 44. cSignificantly different from individuals with HTG without obesity. dSignificantly different from individuals with NTG with obesity. eSignificantly different from individuals with NTG without abdominal obesity.
  3. Subjects characteristics according to the presence of hypertriglyceridemia and abdominal obesity.
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us